Jasper Therapeutics Shares Briquilimab Data at AAAAI Annual Meeting

Jasper Therapeutics, Inc., a biotechnology company based in Redwood City, California, is advancing in the development of briquilimab, a promising antibody therapy targeting the c-Kit receptor to treat diseases driven by mast cells. These include chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. At the AAAAI 2025 Annual Meeting in San Diego, the company presented recent clinical data from its Phase 1b/2a BEACON study and other preclinical studies related to briquilimab.

The BEACON study update, reflecting data as of January 31, 2025, incorporates an additional month of dosing and observation for the 49 participants initially reported on January 8, 2025. Briquilimab has shown continued promise, maintaining a favorable safety profile with no new adverse events linked to its c-Kit blocking mechanism. This ongoing success supports plans to advance briquilimab into a registrational program for CSU, with a Phase 2b adaptive study set to begin in the latter half of 2025. Further clinical data, particularly from patients receiving doses of 180mg and higher, is expected to guide final dose selection by mid-2025.

Dr. Thomas B. Casale, a Professor of Medicine and Pediatrics at the University of South Florida Morsani College of Medicine, expressed satisfaction with the updated findings from the BEACON study. The results indicate that briquilimab produces rapid and significant clinical responses in patients with moderate to severe CSU who have previously been treated with omalizumab. The safety profile remains encouraging, with a low occurrence of c-Kit related adverse events, which were minor and did not necessitate any dose adjustments. The drug's clearance rate, coupled with early Tmax observations, suggests a swift onset of clinical benefits, reinforcing briquilimab's potential as a unique treatment option for CSU patients.

Ronald Martell, President and CEO of Jasper, highlighted the excitement surrounding the efficacy and safety data emerging from the BEACON study. He noted that briquilimab could differentiate itself from existing and experimental therapies in terms of its rapid action, depth of response, and safety. With a growing number of participants in both the BEACON and SPOTLIGHT studies, as well as an open-label extension study, Jasper anticipates reporting on approximately 70 additional patients treated with higher doses of briquilimab around mid-2025. This data will be crucial for the Phase 2b study planned for later this year.

During the AAAAI 2025 Annual Meeting, several presentations highlighted Jasper's research. These included reports on briquilimab's ability to effectively deplete mast cells across multiple tissues in mouse models and its potential to inhibit SCF/c-Kit signaling, leading to mast cell apoptosis. Other studies examined briquilimab's effectiveness in mouse models of dermatitis, demonstrating its capacity to prevent or treat inflammation in skin conditions.

Jasper Therapeutics continues to focus on briquilimab as a treatment for mast cell-related diseases. This monoclonal antibody works by blocking the stem cell factor from interacting with the c-Kit receptor, disrupting crucial cell survival signals and resulting in mast cell depletion and reduced inflammation. Clinical trials for briquilimab are ongoing, targeting conditions like CSU, CIndU, and asthma, with demonstrated positive outcomes in both patients and healthy volunteers.